• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by EVP, CLO & Secretary Merrill Stevin Todd

    6/23/25 4:15:04 PM ET
    $TMHC
    Homebuilding
    Consumer Discretionary
    Get the next $TMHC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Merrill Stevin Todd

    (Last) (First) (Middle)
    4900 N. SCOTTSDALE ROAD,
    SUITE 2000

    (Street)
    SCOTTSDALE AZ 85251

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Taylor Morrison Home Corp [ TMHC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, CLO & Secretary
    3. Date of Earliest Transaction (Month/Day/Year)
    06/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to buy) $57.42 06/18/2025 A 2,642 (1) 06/18/2035 Common Stock 2,642 (2) 2,642 D
    Restricted Stock Units (3) 06/18/2025 A 2,886 (4) (4) Common Stock 2,886 (5) 2,886 D
    Explanation of Responses:
    1. Subject to certain conditions, the options will generally vest in equal installments of 25% on each of June 18, 2026, June 18, 2027, June 18, 2028 and June 18, 2029.
    2. The options were granted to the Reporting Person in accordance with the Taylor Morison 2013 Omnibus Equity Award Plan, as amended (the "Equity Plan").
    3. Each restricted stock unit represents a contingent right to receive one share of Common Stock.
    4. Subject to certain conditions, the restricted stock units will vest in three installments of approximately 33 1/3% on each of June 18, 2026, June 18, 2027 and June 18, 2028.
    5. The RSUs were granted to the Reporting Person in accordance with the Equity Plan.
    /s/ Todd Merrill 06/23/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TMHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMHC

    DatePrice TargetRatingAnalyst
    5/5/2025$70.00Buy
    BofA Securities
    3/6/2025$55.00Sell → Neutral
    Seaport Research Partners
    1/27/2025Neutral → Sell
    Seaport Research Partners
    1/8/2025$76.00Peer Perform → Outperform
    Wolfe Research
    12/11/2024$75.00 → $90.00Equal Weight → Overweight
    Barclays
    10/25/2024$85.00Neutral → Outperform
    Wedbush
    8/19/2024$78.00Neutral → Buy
    BTIG Research
    7/24/2024$75.00Outperform
    Raymond James
    More analyst ratings